Brokers Set Expectations for Septerna FY2025 Earnings

Septerna, Inc. (NASDAQ:SEPN - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Septerna in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($2.58) for the year. Cantor Fitzgerald has a "Overweight" rating and a $50.00 price objective on the stock. The consensus estimate for Septerna's current full-year earnings is ($7.11) per share.

A number of other analysts also recently weighed in on SEPN. TD Cowen assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued a "buy" rating on the stock. JPMorgan Chase & Co. initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an "overweight" rating and a $38.00 price objective on the stock. Finally, Wells Fargo & Company initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They set an "overweight" rating and a $43.00 target price for the company.

Septerna Trading Down 5.2 %

Shares of NASDAQ:SEPN traded down $1.00 on Thursday, hitting $18.38. The company had a trading volume of 157,277 shares, compared to its average volume of 199,398. Septerna has a 1 year low of $15.86 and a 1 year high of $28.99. The stock's 50-day moving average is $22.49.

Insider Buying and Selling at Septerna

In related news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the stock in a transaction that occurred on Monday, October 28th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the completion of the transaction, the insider now owns 6,215,591 shares of the company's stock, valued at approximately $111,880,638. This trade represents a 6.34 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Institutional Investors Weigh In On Septerna

A hedge fund recently bought a new stake in Septerna stock. SG Americas Securities LLC acquired a new position in Septerna, Inc. (NASDAQ:SEPN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 8,095 shares of the company's stock, valued at approximately $185,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.